Integrin-mediated transforming growth factor-β activation, a potential therapeutic target in fibrogenic disorders

SL Nishimura - The American journal of pathology, 2009 - Elsevier
SL Nishimura
The American journal of pathology, 2009Elsevier
A subset of integrins function as cell surface receptors for the profibrotic cytokine
transforming growth factor-β (TGF-β). TGF-β is expressed in an inactive or latent form, and
activation of TGF-β is a major mechanism that regulates TGF-β function. Indeed, important
TGF-β activation mechanisms involve several of the TGF-β binding integrins. Knockout mice
suggest essential roles for integrin-mediated TGF-β activation in vessel and craniofacial
morphogenesis during development and in immune homeostasis and the fibrotic wound …
A subset of integrins function as cell surface receptors for the profibrotic cytokine transforming growth factor-β (TGF-β). TGF-β is expressed in an inactive or latent form, and activation of TGF-β is a major mechanism that regulates TGF-β function. Indeed, important TGF-β activation mechanisms involve several of the TGF-β binding integrins. Knockout mice suggest essential roles for integrin-mediated TGF-β activation in vessel and craniofacial morphogenesis during development and in immune homeostasis and the fibrotic wound healing response in the adult. Amplification of integrin-mediated TGF-β activation in fibrotic disorders and data from preclinical models suggest that integrins may therefore represent novel targets for antifibrotic therapies.
Elsevier